FGL vs NA-Selank
A side-by-side research comparison of FGL and NA-Selank across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FGL | NA-Selank |
|---|---|---|
| Full name | FGL (NCAM-Derived Peptide) | N-Acetyl Selank (Acetylated Selank) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. | Same tuftsin-derived mechanism as Selank with acetyl group providing protease resistance; modulates GABA, enhances BDNF. |
| Molecular weight | ~1,800 Da | 793.91 Da |
| Half-life | 4-8 hours | ~5-10 minutes (effective 4-6 hours) |
| Bioavailability | Moderate (SubQ, partial BBB crossing) | ~95% intranasal |
| Typical dose | 1-5 mg/kg (research) | 200-400 mcg |
| Frequency | Daily or every other day | 1-2x daily |
| Route | Subcutaneous | Intranasal spray |
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
NA-Selank reported benefits
- Enhanced anxiolytic effect
- Improved stability
- Better bioavailability
- Cognitive focus
- Stress resilience
Related comparisons
Research and educational reference only. Not medical advice.